[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer---female\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer---female":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,67,90,122,155,181,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642557","comparison-immune-response-in-paravertebral-and-erector-spinal-plane-block-in-breast-cancer-patients-100642557",false,"NCT07648810","Comparison Immune Response in Paravertebral and Erector Spinal Plane Block in Breast Cancer Patients","Immunologic Response in Breast Cancer Before and After Application of Paravertebral and Erector Spinae Plane Block","IRPVBESP","Inclusion Criteria:\n\n* ASA I and ASA II status, normal BMI\n\nExclusion Criteria:\n\n* ASA III and ASA IV status, coagulopathy, chronic opioid use, diabetes, local infection of the skin","FEMALE","18 Years","70 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to find the difference in immune response between two types of regional anesthesia in female patients suffering from breast cancer.\n\nThe main question it aims to answer is there a difference in the immune response between paravertebral block and erector spinal plane block.\n\nHypothresis of the study is that paravertebral block with propofol induces less immune response in surgical treatment of breast cancer patients than erector spinal plane block.\n\nParticipants will be asked to sign the informant consent. They will be given either paravertebral block or erector spinae plane block with general anesthesia using propofol. Their venous blood will be taken 1 hour prior surgery and 24 and 48 hours after surgery.",[28],"Breast Cancer - Female","NOT_YET_RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":32,"type":22},{"date":36,"type":22},"2027-04-15",{"name":38,"class":39},"Clinical Hospital Center Rijeka","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100639682","effects-of-negative-pressure-wound-bandaging-after-mastectomy-100639682","NCT07607366","Effects of Negative Pressure Wound Bandaging After Mastectomy","Is Negative Pressure Wound Therapy Associated With a Decreased Risk of Postoperative Seroma in Breast Cancer Patients Who Have Undergone Mastectomy?","NEPTAM","Inclusion Criteria:\n\n* Breast cancer patients undergoing mastectomy\n* Female\n* Age \\>= 18 years\n\nExclusion Criteria:\n\n* Direct reconstruction with implants\n* The use of Harmonic Johnson and Johnson instrument during surgery",{"count":49,"type":22},76,[25],"Participant information sheet Mastectomy is a surgical method used to treat breast cancer. A mastectomy involves the removal of the entire breast. A common postoperative complication after a mastectomy is seroma, i.e. an abnormal accumulation of serous fluid in the wound cavity. At present, at Falu Lasarett, we use conventional dressings on the wound after the operation as well as an active drainage that is left in place for a couple of days. There is research that suggests that negative pressure dressings can promote wound healing and reduce the formation of seroma. The purpose of this study is to investigate whether negative pressure dressings reduce the risk of postoperative seroma compared to regular dressings. We will also look at whether it reduces the risk of other postoperative complications such as infection, bleeding and wound healing problems. We are asking all patients who will undergo a mastectomy in 2025 if they want to participate in our study. The Director of Research, Education and Innovation is the authorized representative of the research principal (which is the legal entity Region Dalarna). Research principal means the organization responsible for the project. The research is approved by the Ethics Review Authority, the registry number for the trial at the Ethics Review Authority is 2025-00006-01. How does the project work? Participating in our study means that on the day of surgery you will be randomized between two groups. One group will receive conventional wound dressings, and the other group will receive PICO negative pressure dressings. The negative pressure dressing is connected to a small canister that is worn for 7 days. Just like today, there will be a return visit to the nurse in the surgery ward after a day to check and possibly remove the active drain. There will also be a return visit to the doctor after 2-3 weeks for results of the tissue analysis and information about further treatment. The additional visit if you participate in our study is a return visit to the nurse after 7 days to remove the PICO negative pressure dressing (if you belong to that group). A return visit to the nurse is also planned after 6 months as a follow-up. If you have any questions or problems, you can contact your contact nurse. Possible consequences and risks of participating in the project The PICO negative pressure dressing is connected to a cord with a small canister that must be carried with you. The canister fits in a pocket. The canister is on 24 hours a day and emits a light vibration sound. What happens to your data? The project will collect and register information about you. Information about your medical history, measurements, medications, type of surgical procedure, number of return visits after surgery and postoperative complications will be collected from your medical record to analyze our results. The data will be pseudonymized and entered into a password-protected Excel document for analysis. The code key is stored in a lock-protected Excel file. The code key is processed so that unauthorized persons cannot access it. Your answers and your results will be processed so that unauthorized persons cannot access them. The code key and research data are stored for 10 years in accordance with research ethics because it should be possible to go back to the research data and re-analyze if question marks arise about our analysis methods. The data protection officer of Region Dalarna is responsible for your personal data. According to the EU Data Protection Regulation, you have the right to access the data about you that is handled in the project free of charge, and to have any errors corrected if necessary. You can also request that data about you be deleted and that the processing of your personal data be restricted. However, the right to deletion and restriction of processing of personal data does not apply when the data is necessary for the current research. If you would like to access the data, please contact the principal investigator (Rebecca Paul, rebecca.paul@regiondalarna.se, 023 490760). The data protection officer can be reached at dataskyddsombud@regiondalarna.se, Tel: 023-490000. If you are dissatisfied with how your personal data is processed, you have the right to file a complaint with the Swedish Data Protection Authority, which is the supervisory authority. How do you get information about the results of the project? You can access your individual data in your medical record. The results of the entire study will be reported internally at Kirurgkliniken Falu Lasarett and are intended to be published in a scientific journal. Unforeseen findings will be handled through follow-up and, if necessary, treatment. Insurance and compensation Patient insurance valid through the research principal. You will not receive compensation as the study is part of a planned procedure. Participation is voluntary.",[28],[54,55],"Breast cancer. Mastectomy. Negative pressure wound therapy. Seroma.","Surgical site complications.","RECRUITING","2026-05-19",{"date":59,"type":33},"2026-05-26",{"date":61,"type":33},"2025-03-01",{"date":63,"type":22},"2027-09-01",{"name":65,"class":39},"Dalarna County Council, Sweden",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":66},"100633654","the-effect-of-psychosocial-support-on-improving-breast-cancer-patients-response-to-medical-treatment-100633654","NCT07529496","The Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical Treatment","A Randomized Controlled Trial Assessing the Effect of Psychosocial Support on Improving Breast Cancer's Patients Response to Medical Treatment","Inclusion Criteria:\n\n* age between 20-40 Being Palestinian female from west bank and Jerusalem\n* Diagnosed with stage I-III breast cancer.\n* Currently receiving active medical treatment.\n* Able to provide consent and participate in the intervention.\n\nExclusion Criteria:\n\n* being male.\n* holding other nationalities than Palestinian or living outside the westbank or Jerusalem.\n* Younger than 20 or older than 40 years old.\n* Uncooperative with interviewer\n* Terminally ill (stage IV).\n* Receiving palliative care only.","20 Years","40 Years",{"count":77,"type":22},160,[25],"The goal of this clinical trial is to evaluate the effect of psychosocial therapy on improving treatment response among breast cancer patients receiving chemotherapy. Participants will be randomized to receive standard medical treatment alone or combined with structured psychosocial therapy. Outcomes include treatment response, psychological well-being, and quality of life.\n\n1. Do psychosocial interventions affect the response to breast cancer treatment?\n2. How do societal attitudes toward psychological and social care influence the willingness of breast cancer patients in Palestine to seek psychosocial interventions?",[28],"2026-04-07",{"date":83,"type":33},"2026-04-14",{"date":85,"type":22},"2026-05-01",{"date":87,"type":22},"2027-01-15",{"name":89,"class":39},"Al-Quds University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":66},"100630031","supporting-health-including-endocrine-treatment-for-long-duration-100630031","NCT07482384","Supporting Health Including Endocrine Treatment for Long Duration","Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention","SHIELD","Inclusion criteria\n\nParticipants will be eligible if they meet the following eligibility criteria:\n\n* Female\n* Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer\n* Premenopausal\n* In active treatment (including long-term endocrine therapy) at the time of enrollment\n* Able to speak, understand and read English\n* Access to a US-based mobile phone number\n* Cognitively able to complete study requirements\n* Ability to access medical records from treating hospital (DFCI)\n* Willing to provide cell phone number and\u002For email address and willing to receive email, mobile push notifications, and\u002For text messages from the study team\n\nExclusion criteria\n\nParticipants will be ineligible if they meet any of the following criteria:\n\n* Individuals under age 18 or over age 50 at initial breast cancer diagnosis\n* Patients with breast cancer who are not being treated with ET\n* Stage IV or metastatic breast cancer\n* Pregnant patients\n* Individuals who do not have a US mobile phone number\n* Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.","49 Years",{"count":100,"type":22},30,[25],"This research is being done to pilot an intervention which aims to test a new web- and mobile application (\"app\")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.",[104,28,105,106,107],"Breast Cancer","Breast Carcinoma","ER Positive Breast Cancer","PR-Positive Breast Cancer",[109,110,111,112,96],"Breast cancer","Breast cancer female","Breast carcinoma","ER+","2026-03-16",{"date":115,"type":33},"2026-03-19",{"date":117,"type":22},"2026-05",{"date":119,"type":22},"2027-05",{"name":121,"class":39},"Dana-Farber Cancer Institute",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":17,"minAge":75,"maxAge":19,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":141,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":66},"100618429","validation-of-the-oncoliq-test-for-the-early-detection-of-breast-cancer-100618429","NCT07331506","Validation of the Oncoliq Test for the Early Detection of Breast Cancer.","Inclusion Criteria:\n\nGroup 1 - Breast Cancer:\n\nAge between 40 and 70 years Diagnosis of breast cancer at any stage No prior surgical treatment No prior antineoplastic treatment Pathology report available at the time of enrollment Signed informed consent\n\nGroup 2 - No Cancer (Control):\n\nAge between 50 and 70 years No diagnosis or personal history of any type of cancer Digital mammography and breast ultrasound showing no breast pathology (BI-RADS 1 or 2) Signed informed consent\n\nExclusion Criteria:\n\nRefusal to sign the informed consent Communication issues that hinder understanding (hearing loss, blindness, intellectual disability, or dementia) Venipuncture for blood collection impracticable or posing a risk Personal history of previous cancer",true,{"count":130,"type":22},300,"OBSERVATIONAL","Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagnostic methods results in late diagnoses, leading to 1 in every 6 people dying from cancer today.\n\nMicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are found both inside cells and in bodily fluids such as blood and urine. Several studies have demonstrated their role in human diseases, especially cancer, where tumors release miRNAs into the bloodstream that can be used as biomarkers for early detection.\n\nThe research and development team at Oncoliq SAS identified a panel of miRNAs associated with breast cancer, with a detection performance of 82% sensitivity and 83% specificity, validated in exploratory and preliminary confirmatory studies. These results led to the filing of a patent based on liquid biopsy technology.\n\nThe objective of this protocol is to establish a panel of miRNAs for the early detection of breast cancer using samples from breast cancer patients and a cancer-free control group. Validation of the miRNAs will be carried out through RT-qPCR. This stage constitutes the analytical validation of the biomarkers, with the goal of developing an algorithm capable of classifying individuals with and without breast cancer. In future stages, a pilot clinical trial is planned to evaluate test implementation and clinical validation.",[134,135,136,137,138,139,140,28],"Breast Cancer Detection","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer Female","Breast Cancer - Ductal Carcinoma in Situ (DCIS)","Breast Cancer - Infiltrating Ductal Carcinoma","Breast Cancer With Low to Intermediate HER2 Expression","Breast Cancer (Early Breast Cancer)",[109,142,143,144],"Detection","Liquid biopsy","miRNAs","2026-01-13",{"date":147,"type":33},"2026-01-15",{"date":149,"type":33},"2025-10-17",{"date":151,"type":22},"2026-02-28",{"name":153,"class":154},"Oncoliq US Inc","INDUSTRY",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":66},"100601910","comparing-patient-reported-outcomes-and-clinical-outcomes-based-on-different-scar-placement-in-patients-undergoing-standard-breast-conserving-surgery-for-breast-cancer-the-prom-s-study-100601910","NCT07116642","Comparing Patient Reported Outcomes and Clinical Outcomes Based on Different Scar Placement in Patients Undergoing Standard Breast Conserving Surgery for Breast Cancer: The PROM-S Study.","Comparison of Patient Reported and Clinical Outcome Measures Based on Scar Placement in Patients Undergoing Breast Conserving Surgery (PROM-S Study)","PROM-S","Inclusion Criteria:\n\n* Female patients ≥18 years of age\n* Able to provide written informed consent\n* Invasive breast cancer or ductal carcinoma in situ (DCIS) suitable for sBCS (including multifocal cancers requiring x2 wires or magseeds)\n* Able to understand and complete the questionnaire\n\nScar over the lesion defined as radial, transverse, vertical, oblique scar over the tumour lesion location in the breast Remote incisions defined as lateral perimeter\u002Fperiareolar\u002Finfra-mammary fold\u002F benelli\u002Fhemi-batwing\n\n* No restrictions on tumour size (decision on suitability for sBCS will be based on clinical assessment)\n* Any axillary nodal staging status\n* Bilateral cancers allowed\n* Post neo-adjuvant chemotherapy (NACT) allowed\n\nExclusion Criteria:\n\n* Male patients (BCS not proven as standard of care) or transgender\n* Patients undergoing oBCS (such as wise pattern, vertical scar mastopexy incision pattern or volume replacement chest wall perforator flap)\n* Patients undergoing mastectomy with or without immediate autologous or implant reconstruction\n* Patients requiring nipple excision (central wide local excision)\n* Patients undergoing wide local excision under local anaesthetic\n* Women not able or willing to give informed consent\n* Where close tumour proximity to skin or skin involvement necessitates skin excision over the tumour\n* Patients diagnosed with locoregional recurrence\n* Patients diagnosed with associated distant metastasis\n* Patients undergoing diagnostic excision surgery for atypical breast lesions or benign lesions\n* Patients diagnosed with phyllodes lesion\n* Patients who have had previous ipsilateral breast surgery (any type)",{"count":164,"type":22},100,"This study is for patients with breast cancer and the objective is to compare patient reported outcome measures (PROMs) based on scar placement in patients undergoing standard breast-conserving surgery (sBCS). BCS has become the standard of care for eligible patients with breast cancer (current UK national BCS rate is 60%).\n\nScar placement for sBCS can be divided into two groups: those directly over the cancer, or those in remote locations (e.g. around the nipple, near the armpit, the lower part of the breast, where the breast and the chest meet etc.) with the aim of hiding the scar in more visually acceptable locations on the breast. Multiple factors determine where the scar is placed such as aesthetics, other health conditions, location of the cancer, etc. However, it is currently unclear whether the location of scar placement for sBCS affects patient reported outcomes.\n\nThe growing importance on breast cosmesis has led to more attention from clinicians and patients with regards to the selection of surgical incision placement for sBCS. By using a validated questionnaire (BREAST-Q), we wish to assess if there is any difference in PROMs based on scar placement (over the lesion vs. remote) in patients undergoing sBCS.\n\nIt is anticipated that the study results will help champion and guide care for future breast cancer patients, as well as providing an insight into how patient satisfaction may vary between different sBCS approaches.\n\nThis questionnaire study will include consecutive patients undergoing sBCS at Leeds Teaching Hospitals NHS Trust.\n\nParticipation in this non-randomised study will not impact on routine clinical care or decision making for the type of surgery planned or scar placement choice. Patients will be asked to complete the BREAST-Q questionnaire prior to surgery, after 2 weeks, as well as 3 and 12 months after surgery.",[28,167],"Surgery of Breast Cancer",[169,170,171],"breast cancer","surgery","patient reported outcomes","2025-08-06",{"date":174,"type":33},"2025-08-11",{"date":176,"type":33},"2025-02-20",{"date":178,"type":22},"2027-06",{"name":180,"class":39},"The Leeds Teaching Hospitals NHS Trust",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100600896","phase-2-prospective-multicenter-single-arm-trial-ak112--nab-paclitaxelcarboplatin-neoadjuvant-for-tnbc-100600896","NCT07103447","Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel\u002FCarboplatin Neoadjuvant for TNBC","A Prospective, Multicenter, Single-Arm Study of AK112 in Combination With Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Treatment for Triple-Negative Breast Cancer","Inclusion Criteria:\n\n1. Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is willing to comply with all trial procedures.\n2. Eligibility by Age and Gender: Female participants aged ≥18 years and ≤75 years on the day of signing the informed consent form.\n3. Pathological Confirmation of Disease: Histopathologically confirmed diagnosis of T1-4N0-3M0 (except for T1N0M0) triple-negative invasive breast cancer, defined as negative for estrogen receptor (ER) and progesterone receptor (PgR) (immunohistochemistry: ER, PR \\\u003C 1%), and human epidermal growth factor receptor 2 (HER2) (immunohistochemistry HER2 \"0\\~1+\"; or immunohistochemistry HER2 \"2+\" with no amplification on HER2 FISH gene testing).\n4. Measurable Lesion: At least one lesion measurable according to RECIST v1.1 criteria. Participants diagnosed at an external institution agree to provide archived or freshly obtained tumor tissue samples (formalin-fixed paraffin-embedded \\[FFPE\\] tissue blocks or at least 25 unstained tumor tissue slides) for pathology review.\n5. Planned Surgical Treatment: Participants are scheduled to undergo definitive surgical resection of breast cancer, including either breast-conserving surgery or mastectomy, along with sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND), and are planned to receive neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n1. Prior Anti-Cancer Treatments.\n2. Received systemic anti-cancer treatment, including chemotherapy, radiotherapy, immunotherapy, targeted therapy (within 2 weeks for small molecule targeted therapies), or biological agent treatment within 4 weeks before enrollment.\n3. Received palliative local treatments within 2 weeks before enrollment.\n4. Received systemic non-specific immune modulatory treatments (e.g., interleukins, interferons, thymopeptides) within 2 weeks before enrollment.\n5. Received traditional Chinese medicine or Chinese patent medicines with anti-cancer indications within 2 weeks before enrollment.\n6. Prior PD-1\u002FPD-L1 Treatment.\n7. Previously received treatment with PD-1 inhibitors or PD-L1 inhibitors.\n8. Concurrent Participation in Other Clinical Studies.\n9. Currently participating in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study.\n10. History of Other Malignancies:\n\n(1) Has a history of other malignant tumors within 5 years prior to enrollment or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and thyroid cancer.\n\n(2) Active Autoimmune Diseases: Has active autoimmune diseases that required systemic treatment (such as corticosteroids) within 2 years before enrollment, or has autoimmune diseases that the investigator judges may recur or require planned treatment.","75 Years",{"count":190,"type":22},54,[192],"PHASE2","This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC.",[28],[196],"AK112 combining chemothrapy, neoadjuvant therapy, TNBC","2025-08-02",{"date":199,"type":33},"2025-08-05",{"date":201,"type":22},"2025-09-10",{"date":203,"type":22},"2028-12-31",{"name":205,"class":39},"Shuangyue Liu",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":212,"maxAge":188,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":66},"100589273","effects-of-two-strength-exercise-programs-on-upper-limb-functionality-in-breast-cancer-100589273","NCT06952270","Effects of Two Strength Exercise Programs on Upper Limb Functionality in Breast Cancer","Inclusion Criteria:\n\n* Pathological diagnosis of breast cancer.\n* Patients who have undergone a mastectomy, including unilateral, total breast, or breast-conserving surgery.\n* Postoperative chemotherapy or radiotherapy as required.\n* No other malignant tumors in the last 5 years.\n* Absence of contraindications related to physiotherapy or physical exercise.\n* Willingness to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Metastasis to other organs and tissues (liver, kidney, lung, brain, etc.) that prevent participation in the exercise program.\n* Underlying heart disease, cerebrovascular disease, or mental illness that impairs proper execution of the exercise program.\n* Pre-existing shoulder pathology before surgery.\n* Inability to understand the plyometric exercise program.","25 Years",{"count":214,"type":22},24,[25],"The goal of this experimental study is to evaluate the effect of a therapeutic exercise program based on upper limb plyometric exercises in breast cancer patients and breast cancer survivors to determine changes in upper limb functionality.\n\nThe main question it aims to answer is: Does upper limb plyometric strength exercise improve upper limb dysfunctions in breast cancer patients and survivors? The researchers will compare the effects of plyometric exercise with the effects of strength training exercise to determine whether plyometric exercise improves shoulder dysfunctions in breast cancer patients and survivors.\n\nParticipants from the Pontevedra group will undergo the intervention using plyometric exercise (Experimental Group), while those from the Vigo group will perform strength training exercise (Control Group). They will complete two sessions per week for six weeks. Outcome variables related to upper limb functionality will be assessed at baseline and after the intervention.",[218,104,219,28],"Breast Cancer Survivor","Breast Cancer Patients",[169,221,222,223,224,225,226],"plyometric exercise","upper limb","strength training","exercise","Recovery of Function","clinical trial","2025-04-26",{"date":229,"type":33},"2025-04-30",{"date":231,"type":22},"2025-05-02",{"date":233,"type":22},"2025-07",{"name":235,"class":39},"University of Vigo"]